Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial.

Huddart, Robert A and Hall, Emma and Lewis, Rebecca and Porta, Nuria and Crundwell, Malcolm and Jenkins, Peter J and Rawlings, Christine and Tremlett, Jean and Campani, Leila and Hendron, Carey and Hussain, Syed A and James, Nicholas D (2019) Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. European urology. ISSN 1873-7560.

Full text not available from this repository.
Official URL: https://www.europeanurology.com/article/S0302-2838...

Abstract

BACKGROUND

BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer, demonstrated improvement of local control and bladder cancer-specific survival from the addition of concomitant 5-fluorouracil and mitomycin C to radiotherapy.

OBJECTIVE

To determine the impact of treatment on the health-related quality of life (HRQoL) of BC2001 participants.

DESIGN, SETTING, AND PARTICIPANTS

458 UK patients with T2-T4a N0 M0 transitional cell carcinoma of the bladder.

INTERVENTION

Patients were randomised to the chemotherapy comparison (radiotherapy, 178, or chemoradiotherapy, 182); and/or to the radiotherapy comparison (standard, 108, or reduced high-dose volume radiotherapy, 111).

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS

Patients completed Functional Assessment of Cancer Therapy-Bladder (FACT-BL) questionnaires at baseline, end of treatment (EoT), and 6, 12, 24, 36, 48, and 60 months after radiotherapy. The primary endpoint was change from baseline in the bladder cancer subscale (BLCS) at 12 months.

RESULTS AND LIMITATIONS

Data were available for 331 (92%) and 204 (93%) participants at baseline and for 192 (54%) and 114 (52%) at 12 months for the chemotherapy and radiotherapy comparisons, respectively. HRQoL declined at EoT (BLCS -5.06 [99% confidence interval: -6.12 to -4.00, p< 0.001]; overall FACT-B TOTAL score -8.22 [-10.76 to -5.68, p< 0.01]), recovering to baseline at 6 months and remaining similar to baseline subsequently. There was no significant difference between randomised groups at any time point.

CONCLUSIONS

Immediately following (chemo)radiotherapy, a significant proportion of patients report declines in HRQoL, which improve to baseline after 6 months. Two-thirds of patients report stable or improved HRQoL on long-term follow-up. There is no evidence of impairment in HRQoL resulting from the addition of chemotherapy.

PATIENT SUMMARY

Quality of life of bladder cancer patients treated with radiotherapy±chemotherapy deteriorates during treatment, but improves to at least pretreatment levels within 6 months. Addition of chemotherapy to radiotherapy does not affect patient-reported quality of life.

Item Type: Article
Subjects: WJ Urogenital system. Urology
Divisions: Planned IP Care > Urology
Related URLs:
Depositing User: Mr Muneeb Liaquat
Date Deposited: 20 Dec 2019 15:18
Last Modified: 20 Dec 2019 15:18
URI: http://www.repository.uhblibrary.co.uk/id/eprint/2709

Actions (login required)

View Item View Item